BIAFW — bioAffinity Technologies, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1712762 ·
Last close
$0.26
Market Cap
—
52W High
$0.38
52W Low
$0.26
ADV30
2,259
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 1,351,527 | 422,891 | -3,616,976 | -3,630,610 | 7,945,252 | 3,098,366 | 4,283,866 |
| Dec 2025 | 1,538,813 | 638,687 | -3,190,963 | -3,137,466 | 10,960,772 | 6,449,782 | 3,683,116 |
| Sep 2025 | 1,446,066 | 503,855 | -2,292,846 | -5,051,084 | 11,546,369 | 7,669,195 | 2,644,171 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,914,307
Investing CF
$-15,445
Financing CF
$13,583,412
CapEx
$-69,877
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,184,674
Inventory
$77,887
Receivables
$685,235
ST Investments
—
EBIT TTM
$-15,800,991
Pretax Income TTM
$-15,844,600
Interest Exp TTM
$43,609
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,900,985
EBITDA
$-11,968,556
Free Cash Flow
$-6,909,285
Enterprise Value
—
Total Cash
$2,429,719
Total Debt
$1,435,005
Shares Out
—
Trailing EPS
—
Book Value
$8.34
ROE
-1860.2%
ROA
-125.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,107,959 | -10,626,508 | -14,909,754 | 10,960,772 | 3,683,116 | 7,277,656 | -9,328,842 |
| Dec 2024 | 9,362,022 | -8,953,445 | -9,039,831 | 6,513,667 | 3,911,631 | 2,602,036 | -7,264,795 |
| Dec 2023 | 2,532,499 | -7,973,228 | -7,937,011 | 8,221,552 | 3,366,297 | 4,855,255 | -6,037,806 |
| Dec 2022 | 4,803 | -4,011,058 | -8,154,113 | 12,182,125 | 1,138,682 | 11,043,443 | -4,070,845 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $44.60B | $270.97 | — |
| IDXX | IDEXX LABORATORIES INC /DE | $41.68B | $529.06 | — |
| INCY | INCYTE CORP | $25.30B | $124.82 | — |
| MEDP | Medpace Holdings, Inc. | $17.19B | $615.94 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $14.19B | $294.59 | — |
News headlines (Yahoo Finance, 1h cache)
bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection
2026-09-28 09:17 · Yahoo
bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference
2026-09-22 14:41 · Yahoo
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
2026-09-22 12:00 · Yahoo
bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic
2026-09-17 14:21 · Yahoo
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
2026-09-17 12:00 · Yahoo
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
2026-09-09 12:00 · Yahoo
bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right?
2026-09-05 06:13 · Yahoo
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 20:30 · Yahoo
bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update
2026-09-03 12:21 · Yahoo
bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance
2026-09-01 15:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.